GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDDA) » Definitions » 3-Year EPS without NRI Growth Rate

Innate Pharma (FRA:IDDA) 3-Year EPS without NRI Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Innate Pharma 3-Year EPS without NRI Growth Rate?

Innate Pharma's EPS without NRI for the six months ended in Dec. 2023 was €-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Innate Pharma was 77.60% per year. The lowest was -31.30% per year. And the median was 23.50% per year.


Competitive Comparison of Innate Pharma's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Innate Pharma's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Innate Pharma's 3-Year EPS without NRI Growth Rate falls into.



Innate Pharma 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Innate Pharma  (FRA:IDDA) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Innate Pharma 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Innate Pharma's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (FRA:IDDA) Business Description

Industry
Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (FRA:IDDA) Headlines

No Headlines